GlassScriptPhysician profile
Adam A Bierzynski
NPI 1386937613
$18,837.55
in general payments reported to CMS, 2019-2025
30 companies · $2,413 in 2025
The $2,413 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,893 · 2020: $1,230 · 2021: $5,765 · 2022: $1,656 · 2023: $2,501 · 2024: $2,380 · 2025: $2,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,294.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $4,888.65 | 2021-2025 | Nexletol |
| Abbott Laboratories | $4,042.07 | 2019-2025 | Aveir, Absolute Pro, Jot Dx |
| Medtronic, INC. | $2,128.08 | 2022-2025 | Reveal Linq, Linq II, Micra |
| Siemens Medical Solutions USA, INC. | $1,932.27 | 2019-2020 | |
| Inari Medical, INC. | $1,121.91 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $567.29 | 2019-2025 | |
| Boston Scientific Corporation | $469.79 | 2022-2025 | Watchman Flx, Watchman Access System |
| Cardiovascular Systems INC. | $400.05 | 2019-2022 | |
| Pfizer INC. | $345.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $337.57 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $325.34 | 2021-2024 | Farxiga |
| Abiomed | $297.07 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $275.47 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $274.04 | 2022-2025 | Camzyos, Eliquis |
| Philips North America LLC | $248.43 | 2020-2024 | (Cm9) Amb Mon & Diag Und |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.83 | 2022-2025 | Jardiance |
| Medtronic Vascular, INC. | $156.31 | 2020 | |
| Novo Nordisk INC | $143.05 | 2023-2025 | Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.37 | 2020-2023 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $135.22 | 2020-2022 | |
| Biosense Webster, INC. | $117.22 | 2022 | |
| Amgen INC. | $94.75 | 2021-2024 | Repatha |
| Amarin Pharma, INC. | $69.32 | 2019-2022 | |
| Cvrx, INC. | $49.81 | 2023 | Barostim Neo System |
| Lilly USA, LLC | $23.34 | 2025 | Zepbound |
| Astellas Pharma US INC | $22.44 | 2021 | |
| Acist Medical Systems, INC. | $22.00 | 2021 | |
| Preventice Services, LLC | $18.27 | 2021 | |
| Ucb, INC. | $16.55 | 2021 | |
| Penumbra, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bierzynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.